Investigations of high molecular weight recombinant protein triblock copolymers demonstrate unique opportunities to systematically modify material microstructure on both nano-and mesolength scales in a manner not been previously demonstrated for protein polymer systems. Significantly, through the biosynthesis of BAB-type copolymers containing flanking, plastic-like end blocks and an elastomeric midblock, virtually cross-linked protein-based materials were generated that exhibit tunable properties in a manner completely analogous to synthetic thermoplastic elastomers. Through the rational choice of processing conditions that control meso-and nanoscale structure, changes of greater than 3 orders of magnitude in Young's modulus (0.03-35 MPa) and 5-fold in elongation to break (250-1300%) were observed. Extensibility of this range or magnitude has not been previously reported for virtually cross-linked copolymers that have been produced by either chemical or biosynthetic approaches. We anticipate that these versatile protein-based thermoplastic elastomers will find applications as novel scaffolds for tissue engineering and as new biomaterials for controlled drug release and cell encapsulation.

Tissue engineered vascular grafts require long fabrication times, in part, due to the requirement of cells from a variety of cell sources to produce a robust load bearing, extracellular matrix. Herein, we propose a design strategy for the fabrication of tubular conduits comprised of collagen fiber networks and elastin-like protein polymers to mimic native tissue structure and function. Dense fibrillar collagen networks exhibited an ultimate tensile strength (UTS) of 0.71 ± 0.06 MPa, strain to failure of 37.1 ± 2.2%, and Young’s modulus of 2.09 ± 0.42 MPa, comparing favorably to an UTS and a Young’s modulus for native blood vessels of 1.4 – 11.1 MPa and 1.5 ± 0.3 MPa, respectively. Resilience, a measure of recovered energy during unloading of matrices, demonstrated that 58.9 ± 4.4% of the energy was recovered during loading-unloading cycles. Rapid fabrication of multilayer tubular conduits with maintenance of native collagen ultrastructure was achieved with internal diameters ranging between 1 to 4 mm. Compliance and burst pressures exceeded 2.7 ± 0.3%/100 mmHg and 830 ± 131 mmHg, respectively, with a significant reduction in observed platelet adherence as compared to ePTFE (6.8 ± 0.05 × 105 vs. 62 ± 0.05 × 105 platelets/mm2, p < 0.01). Using a rat aortic interposition model, early in vivo responses were evaluated at 2 weeks via Doppler ultrasound and CT angiography with immunohistochemistry confirming a limited early inflammatory response (n=8). Engineered collagen-elastin composites represent a promising strategy for fabricating synthetic tissues with defined extracellular matrix content, composition, and architecture.

No abstract

No abstract

Virtually all biomaterials are susceptible to biofilm formation and, as a consequence, device-associated infection. The concept of an immobilized liquid surface, termed slippery liquid-infused porous surfaces (SLIPS), represents a new framework for creating a stable, dynamic, omniphobic surface that displays ultralow adhesion and limits bacterial biofilm formation. A widely used biomaterial in clinical care, expanded polytetrafluoroethylene (ePTFE), infused with various perfluorocarbon liquids generated SLIPS surfaces that exhibited a 99% reduction in S. aureus adhesion with preservation of macrophage viability, phagocytosis, and bactericidal function. Notably, SLIPS modification of ePTFE prevents device infection after S. aureus challenge in vivo, while eliciting a significantly attenuated innate immune response. SLIPS-modified implants also decrease macrophage inflammatory cytokine expression in vitro, which likely contributed to the presence of a thinner fibrous capsule in the absence of bacterial challenge. SLIPS is an easily implementable technology that provides a promising approach to substantially reduce the risk of device infection and associated patient morbidity, as well as health care costs.

Collagen and elastin networks contribute to highly specialized biomechanical responses in numerous tissues and species. Biomechanical properties such as modulus, elasticity, and strength ultimately affect tissue function and durability, as well as local cellular behavior. In the case of vascular bypass grafts, compliance at physiologic pressures is correlated with increased patency due to a reduction in anastomotic intimal hyerplasia. In this report, we combine extracellular matrix (ECM) protein analogues to yield multilamellar vascular grafts comprised of a recombinant elastin-like protein matrix reinforced with synthetic collagen microfibers. Structural analysis revealed that the fabrication scheme permits a range of fiber orientations and volume fractions, leading to tunable mechanical properties. Burst strengths of 239–2760 mm Hg, compliances of 2.8–8.4%/100 mm Hg, and suture retention strengths of 35–192 gf were observed. The design most closely approximating all target criteria displayed a burst strength of 1483 ± 43 mm Hg, a compliance of 5.1 ± 0.8%/100 mm Hg, and a suture retention strength of 173 ± 4 gf. These results indicate that through incorporation of reinforcing collagen microfibers, recombinant elastomeric protein-based biomaterials can play a significant role in load bearing tissue substitutes. We believe that similar composites can be incorporated into tissue engineering schemes that seek to integrate cells within the structure, prior to or after implantation in vivo.

Key Points Targeting of an anticlotting drug to activated platelets promises effective blood clot prevention without bleeding side effects.

Chemoselective conjugation of an azido-functionalized thrombomodulin to pancreatic islets was achieved by Staudinger ligation to a surface-bound bifunctional poly(ethylene glycol) linker. The presence of the tethered thrombomodulin resulted in a significant increase in the production of activated protein C with a reduction in islet-mediated thrombogenicity. This report highlights the potential of tissue-targeted chemistry to reduce donor cell mediated procoagulant and proinflammatory responses.